Amarin's CEO resigns, leaving former interim chief to take over struggling drugmaker

After Amarin's tussle with investor group Sarissa Capital led to a restructuring and a board shuffle, the struggling drugmaker is undergoing its third CEO shake-up in just over a year.

This time, the company is giving a familiar face the official CEO title, tapping former interim chief Aaron Berg for the post.